Revolution Medicines Reports 60.7% Response Rate in Early Pancreatic Cancer Study
In a 61-patient Phase 1/2 study reported by TradingView, daraxonrasib plus chemotherapy reached a 60.7% confirmed response rate in pancreatic cancer.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
TradingView reports that Revolution Medicines recorded a confirmed response rate of 60.7% among 61 patients with first-line metastatic pancreatic cancer. The combination of daraxonrasib with gemcitabine and nab-paclitaxel also produced a median progression-free survival of 12.8 months.
The study was open-label, with a median follow-up of 18.3 months. The two-year overall survival reached 76.6%, and the median duration of response was 11.1 months. These results come from an early-stage study rather than a controlled comparison.
The next major milestone is the Phase 3 RASolute 303 trial, which will compare daraxonrasib regimens with chemotherapy alone.
why it matters
For the company's shares this is a positive signal, but the sample is small and the design is open-label, so the market will wait for Phase 3 confirmation. The news concerns one company and a narrow oncology segment, so it is unlikely to move broader markets.
market impact
Revolution Medicines shares: early data supports interest, Phase 3 will be decisive
- Revolution Medicines shares pressure up — positive early efficacy data supports investor interest in the stock
tags
instruments
sources
- Revolution Medicines (RVMD) Reports 60.7% Response Rate in Phase 1/2 Study — TradingView, 19 November 2026 at 23:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗